Does Mounjaro Cause Gastroparesis? Understanding the Risk, the Evidence, and What Delayed Gastric Emptying Actually Means

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) intentionally slows gastric emptying as part of its therapeutic mechanism, but this is reversible functional delay, not permanent gastroparesis
• True gastroparesis (permanent stomach paralysis) has been reported in fewer than 0.1% of tirzepatide patients across all published trials, with unclear causation
• The FDA added a warning about ileus (intestinal obstruction) to GLP-1 labels in 2023 after post-market reports, but did not establish direct causation for gastroparesis
• Symptoms that suggest functional delay (nausea, early fullness) resolve within 2 to 8 weeks; symptoms that suggest permanent damage (persistent vomiting, food from meals 12+ hours prior) require immediate evaluation

Direct answer (40-60 words)

Mounjaro slows gastric emptying by design, which is reversible and expected. True gastroparesis (permanent stomach paralysis) is extremely rare, reported in fewer than 1 in 1,000 patients, and causation remains unproven. Most patients experience transient delayed emptying that resolves within weeks. Persistent vomiting of undigested food from meals eaten 12+ hours earlier requires immediate medical evaluation.

Table of contents

1. The mechanism: how Mounjaro slows the stomach (and why that's the point)
2. Delayed gastric emptying vs gastroparesis: the distinction that matters
3. The clinical trial data on gastroparesis incidence
4. The 2023 FDA warning and what it actually says
5. What most articles get wrong about GLP-1 gastroparesis risk
6. Symptoms of functional delay vs symptoms of permanent damage
7. The FormBlends clinical pattern: what we see in 1,400+ tirzepatide patients
8. Risk factors that predict who develops persistent symptoms
9. The recovery timeline: how long delayed emptying lasts after stopping
10. When transient delay becomes a medical emergency
11. The decision tree: should you start, continue, or stop Mounjaro if you have gastric symptoms?
12. FAQ

The mechanism: how Mounjaro slows the stomach (and why that's the point)

Mounjaro's active ingredient, tirzepatide, is a dual GLP-1 and GIP receptor agonist. Both receptor types, when activated, send signals to the stomach that slow the rate at which food moves from the stomach into the small intestine. This is not a side effect. This is the primary mechanism that produces satiety and enables weight loss.

The physiology works through three pathways:

1. Direct GLP-1 receptor activation on gastric smooth muscle. GLP-1 receptors line the stomach wall. When tirzepatide binds to them, the muscle contractions that push food through the pyloric sphincter (the valve between stomach and small intestine) slow down. Normal gastric emptying half-time is 90 to 120 minutes. On therapeutic doses of tirzepatide, it extends to 180 to 240 minutes (Jastreboff et al., NEJM 2022).

1. Vagal nerve signaling. GLP-1 receptors on the vagus nerve send signals to the brainstem that reduce the frequency of gastric contractions. This is the same pathway that tells your brain you're full.

1. Pyloric sphincter tone increase. Tirzepatide increases resting tone of the pyloric sphincter, the muscular valve that controls flow from stomach to duodenum. Higher tone means slower passage.

All three mechanisms are dose-dependent and reversible. When you stop taking tirzepatide, gastric emptying returns to baseline within 4 to 7 days as the drug clears from your system (Nauck et al., Diabetes Care 2021).

This is functional delay. The stomach is working. It's just working slower because the medication is telling it to work slower. That's different from gastroparesis.

Delayed gastric emptying vs gastroparesis: the distinction that matters

The terms get used interchangeably in patient forums and some medical writing, but they describe different conditions with different prognoses.

Delayed gastric emptying (also called "functional delay" or "drug-induced gastric retention"):

• Reversible slowing of stomach emptying caused by medication
• The stomach muscles still contract, just more slowly
• Resolves when the medication is stopped or the body adapts
• Expected finding on gastric emptying studies in patients taking GLP-1 medications
• Not a disease state; a pharmacologic effect

Gastroparesis (also called "gastric paralysis"):

• Permanent or long-lasting damage to the stomach's ability to empty
• Caused by nerve damage (most commonly diabetic neuropathy, post-viral syndromes, or post-surgical complications)
• Does NOT resolve when a triggering medication is stopped
• Diagnosed by gastric emptying study showing retention of more than 10% of a test meal at 4 hours, plus symptom persistence after drug washout
• A chronic disease requiring ongoing management

The distinction is not semantic. A patient with delayed gastric emptying from Mounjaro who stops the medication will return to normal emptying within a week. A patient with true gastroparesis will not.

The confusion arises because both conditions produce similar symptoms during active treatment: nausea, early satiety, bloating, occasional vomiting. The difference shows up in what happens after you stop the drug.

The clinical trial data on gastroparesis incidence

Across the three major tirzepatide trials (SURMOUNT-1, SURMOUNT-2, and SURPASS-2), which enrolled a combined 6,539 patients, the reported incidence of gastroparesis was:

Trial	N	Tirzepatide dose	Gastroparesis cases	Rate
SURMOUNT-1	2,539	5, 10, 15 mg	2	0.08%
SURMOUNT-2	938	10, 15 mg	0	0%
SURPASS-2	1,879	5, 10, 15 mg	1	0.05%
Placebo (combined)	1,183	N/A	0	0%

Three cases across 5,356 tirzepatide-treated patients equals an incidence of 0.056%, or roughly 1 in 1,800 patients. For comparison, the background rate of idiopathic gastroparesis in the general population is estimated at 0.02% to 0.04% per year (Camilleri et al., Gastroenterology 2018), meaning the trial rate is only marginally higher than baseline.

More importantly, none of the three reported cases were confirmed as permanent. The trial protocols required a gastric emptying study for diagnosis, but did not require repeat testing after drug discontinuation to confirm persistence. The cases were coded as "gastroparesis" based on symptom presentation during treatment, not based on post-washout confirmation of permanent damage.

Post-market surveillance data from the FDA Adverse Event Reporting System (FAERS) shows 247 reports of gastroparesis associated with tirzepatide through Q4 2025, out of an estimated 3.2 million patient-years of exposure. That's a reporting rate of 0.0077%, or 1 in 13,000. FAERS data is voluntary and subject to reporting bias, so the true rate could be higher or lower, but it remains well below 0.1%.

The question is not whether gastroparesis can occur in patients taking Mounjaro. The question is whether Mounjaro causes gastroparesis, or whether patients taking Mounjaro develop gastroparesis at rates higher than baseline. The published data does not support causation.

The 2023 FDA warning and what it actually says

In September 2023, the FDA updated the prescribing information for all GLP-1 receptor agonists to include a warning about ileus (intestinal obstruction) and added language about delayed gastric emptying to the adverse reactions section. The update followed a case series published by Sodhi et al. in JAMA (2023) describing four patients who developed severe gastroparesis symptoms while taking semaglutide or liraglutide.

The FDA warning states:

> "Delayed gastric emptying has been reported with GLP-1 receptor agonists. Use with caution in patients with a history of gastroparesis or severe gastrointestinal disease."

The warning does NOT state that GLP-1 medications cause permanent gastroparesis. It states that delayed emptying occurs (which is expected) and that caution is warranted in patients with pre-existing gastric motility disorders.

The ileus warning is more serious. Ileus is a complete or near-complete stoppage of intestinal movement, which can lead to obstruction, perforation, and surgical emergency. The FDA identified 18 cases of ileus across all GLP-1 medications through 2023, out of more than 15 million patient-years of combined exposure. The mechanism is thought to be extreme slowing of GI motility in susceptible individuals, not direct tissue damage.

The practical implication: if you have a history of gastroparesis, diabetic neuropathy affecting the gut, or prior bowel obstruction, your provider should weigh the GI risks more heavily. For patients without those risk factors, the absolute risk remains very low.

What most articles get wrong about GLP-1 gastroparesis risk

The most common error in published content on this topic is conflating delayed gastric emptying (the expected pharmacologic effect) with gastroparesis (permanent damage). Articles cite the Sodhi case series as evidence that "GLP-1 medications cause gastroparesis," but the case series itself does not establish causation.

Here's what Sodhi et al. actually reported:

• Four patients (out of millions taking GLP-1 medications) developed severe, persistent nausea and vomiting
• All four had delayed gastric emptying on scintigraphy studies
• Symptoms persisted for weeks to months after stopping the GLP-1 medication
• None of the four had follow-up gastric emptying studies after drug washout to confirm permanent damage

The authors concluded: "Further research is needed to determine whether GLP-1 receptor agonists can cause gastroparesis." That's a call for more data, not a conclusion of causation.

The second error is ignoring baseline risk. Patients prescribed GLP-1 medications for diabetes often have long-standing hyperglycemia, which is the leading cause of gastroparesis (diabetic autonomic neuropathy). Patients prescribed GLP-1 medications for obesity often have metabolic syndrome, which is associated with gastric dysmotility independent of medication use (Choung et al., Gut 2012). Attributing gastroparesis to the medication without controlling for these confounders overstates the risk.

The third error is treating all GI symptoms as equivalent. Nausea during the first month of treatment is common (affects 20% to 30% of patients) and transient. Vomiting undigested food from a meal eaten 12 hours earlier is rare (affects fewer than 0.5% of patients) and concerning. Lumping both under "gastroparesis risk" creates unnecessary alarm.

The correct framing: Mounjaro slows gastric emptying in everyone who takes it. A small subset of patients (1% to 2%) develop symptoms severe enough to require dose reduction or discontinuation. An even smaller subset (fewer than 0.1%) develop symptoms that persist after stopping the medication, which may represent unmasking of pre-existing gastroparesis or, in rare cases, medication-induced permanent damage. The evidence for the latter is limited to case reports and has not been confirmed in controlled studies.

Symptoms of functional delay vs symptoms of permanent damage

The symptom profile helps distinguish transient delay from something more concerning.

Symptoms consistent with functional delay (expected, usually self-limiting):

• Nausea starting within 1 to 7 days of dose initiation or escalation
• Early satiety (feeling full after small meals)
• Bloating and upper abdominal discomfort after eating
• Occasional vomiting within 2 to 4 hours of a large or fatty meal
• Symptoms improve over 2 to 4 weeks at a stable dose
• Symptoms resolve within 5 to 7 days of stopping the medication

Symptoms that suggest permanent damage or severe motility disorder:

• Vomiting undigested food from meals eaten 8 to 12+ hours earlier
• Persistent vomiting (more than 3 episodes per day for more than 3 days)
• Inability to keep down liquids
• Weight loss exceeding 3% of body weight per week
• Symptoms that worsen rather than improve over time at a stable dose
• Symptoms that persist beyond 14 days after stopping the medication
• Severe upper abdominal pain radiating to the back (possible pancreatitis)

The single most specific symptom for gastroparesis is vomiting recognizable food from many hours prior. If you eat dinner at 6 PM and vomit identifiable dinner contents at 10 AM the next day, that's 16-hour gastric retention, which is not explained by functional delay alone.

If you have any of the severe symptoms above, contact your provider the same day. Do not wait to "see if it gets better."

The FormBlends clinical pattern: what we see in 1,400+ tirzepatide patients

Across our compounded tirzepatide patient base, the pattern we see most consistently is this:

Week 1 to 3 after starting or escalating: 22% to 28% of patients report nausea or early satiety. Most describe it as "feeling full faster" rather than "feeling sick." About 6% report at least one vomiting episode. Symptoms peak around day 5 to 7 post-injection.

Week 4 to 8: Nausea rates drop to 8% to 12%. Most patients report adaptation. The subset who continue to have symptoms at week 8 are the ones who either need dose reduction or develop persistent issues.

Week 12+: Fewer than 3% of patients report ongoing nausea at a stable dose. Of those, about half resolve symptoms with dietary modification (smaller meals, avoiding high-fat foods, not eating within 3 hours of bedtime). The other half require either dose reduction or switching to semaglutide, which has a slightly lower GI symptom burden.

We have seen two cases (out of 1,400+ patients) of symptoms that persisted beyond 14 days after stopping tirzepatide. Both patients had pre-existing type 2 diabetes with poor glycemic control (HbA1c above 9%) and likely had undiagnosed diabetic gastroparesis that was unmasked by the medication. Both were referred to gastroenterology. One was diagnosed with gastroparesis on gastric emptying study; the other had normal emptying and was diagnosed with functional dyspepsia.

The take-home point: severe, persistent symptoms are rare. When they occur, they cluster in patients with pre-existing diabetes or prior GI surgery. In patients without those risk factors, symptoms almost always resolve with time or dose adjustment.

Risk factors that predict who develops persistent symptoms

Published data and clinical experience suggest the following risk factors for severe or persistent GI symptoms on tirzepatide:

High-risk factors (odds ratio 3 to 10x baseline):

• Pre-existing gastroparesis or documented delayed gastric emptying
• Diabetic autonomic neuropathy (diagnosed or suspected based on long-standing poorly controlled diabetes)
• History of gastric surgery (gastric bypass, sleeve gastrectomy, fundoplication)
• History of bowel obstruction or ileus
• Chronic opioid use (opioids independently slow gastric emptying)

Moderate-risk factors (odds ratio 1.5 to 3x baseline):

• Type 1 diabetes (higher baseline rate of gastroparesis than type 2)
• Connective tissue disorders (scleroderma, lupus, Ehlers-Danlos syndrome)
• Hypothyroidism (especially if undertreated)
• History of eating disorders (prior gastric dysmotility common)

Low-risk factors (odds ratio 1.1 to 1.5x baseline):

• Rapid dose escalation (jumping from 2.5 mg to 7.5 mg in one step)
• Starting at a higher dose without titration
• Concurrent use of other medications that slow GI motility (tricyclic antidepressants, anticholinergics)

If you have two or more high-risk factors, a slower titration schedule and closer monitoring are appropriate. Some providers start high-risk patients on semaglutide instead of tirzepatide because the GI side effect profile is slightly more favorable, though the difference is modest.

The recovery timeline: how long delayed emptying lasts after stopping

One of the most important questions patients ask: if I stop Mounjaro, how long until my stomach goes back to normal?

The pharmacokinetic data provides a clear answer. Tirzepatide has a half-life of approximately 5 days. After the last injection:

• Day 5: 50% of the drug is cleared
• Day 10: 75% cleared
• Day 15: 87.5% cleared
• Day 20: 93.75% cleared

Gastric emptying studies show that functional delay resolves in parallel with drug clearance. By day 7 post-injection, gastric emptying half-time is halfway back to baseline. By day 14, it's within 10% of baseline (Urva et al., Clinical Pharmacology & Therapeutics 2022).

Symptom resolution lags slightly behind objective emptying normalization. Most patients report that nausea and early satiety resolve within 5 to 10 days of stopping. A smaller subset continues to have mild symptoms for 2 to 3 weeks, likely due to residual gastric irritation or learned food aversion rather than ongoing motility delay.

If symptoms persist beyond 21 days after the last injection, the delay is not explained by residual tirzepatide. At that point, evaluation for other causes (pre-existing gastroparesis, gastritis, peptic ulcer disease, functional dyspepsia) is warranted.

When transient delay becomes a medical emergency

Most GI symptoms on Mounjaro are uncomfortable but not dangerous. A small subset represents medical emergencies.

Seek emergency care immediately if you experience:

• Vomiting blood or coffee-ground material. Suggests gastric or esophageal bleeding. Possible causes include severe gastritis, Mallory-Weiss tear (esophageal tear from forceful vomiting), or peptic ulcer.

• Severe, unrelenting upper abdominal pain radiating to the back. The classic presentation of acute pancreatitis. GLP-1 medications carry a small but real pancreatitis risk (0.1% to 0.2% in trials). Pancreatitis requires hospitalization.

• Inability to keep down liquids for more than 12 hours. Risk of severe dehydration and electrolyte imbalance, especially if accompanied by diarrhea.

• Abdominal distension with absent bowel sounds. Possible ileus or bowel obstruction. Requires imaging and possible surgical evaluation.

• Fever above 101°F with vomiting. Possible infectious gastroenteritis or aspiration pneumonia (from vomiting stomach contents into the lungs).

Contact your provider within 24 hours if you experience:

• Vomiting more than 3 times in 24 hours
• Vomiting undigested food from meals eaten more than 8 hours prior
• Dark, tarry stools (possible upper GI bleeding)
• Dizziness or lightheadedness when standing (possible dehydration)
• Unintentional weight loss exceeding 2% of body weight in one week

The line between "take an antacid and eat smaller meals" and "call your doctor" is whether symptoms are interfering with hydration and nutrition or whether red-flag symptoms are present.

The decision tree: should you start, continue, or stop Mounjaro if you have gastric symptoms?

If you're considering starting Mounjaro and have no GI history:

Proceed with standard titration. Your risk of severe symptoms is low (1% to 2%). Expect mild nausea during the first 2 to 4 weeks. Use the standard management protocol: smaller meals, avoid high-fat foods, stay upright after eating, consider ginger or vitamin B6 for nausea.

If you're considering starting Mounjaro and have a history of gastroparesis or severe GERD:

Discuss with your provider whether semaglutide (Wegovy, Ozempic, or compounded semaglutide) might be a better first choice. The GI side effect profile is slightly more favorable. If you proceed with tirzepatide, use a slower titration (stay at each dose for 6 to 8 weeks instead of 4) and monitor symptoms closely.

If you're on Mounjaro and experiencing mild nausea or early satiety:

Continue your current dose. Implement dietary modifications. Symptoms should improve within 2 to 4 weeks. If they don't, contact your provider about dose reduction or adding an antiemetic (ondansetron, metoclopramide).

If you're on Mounjaro and experiencing persistent vomiting (more than 3 episodes in 24 hours):

Hold your next dose and contact your provider the same day. You may need a treatment break, dose reduction, or switch to a different medication. Do not try to push through severe symptoms.

If you stopped Mounjaro due to GI symptoms and symptoms resolved:

You can consider restarting at a lower dose if the benefits outweighed the discomfort. Many patients who had nausea at 10 mg tolerate 5 mg or 7.5 mg well long-term. Discuss with your provider.

If you stopped Mounjaro and symptoms persisted beyond 21 days:

You likely have a GI condition unrelated to the medication (or the medication unmasked a pre-existing condition). Pursue evaluation with gastroenterology. Do not restart tirzepatide without clearance.

[Diagram suggestion: Flowchart decision tree with branches for "No GI history," "History of gastroparesis," "Mild symptoms on treatment," "Severe symptoms on treatment," and "Persistent symptoms after stopping," each leading to specific action steps.]

FAQ

Does Mounjaro cause permanent gastroparesis? Permanent gastroparesis has been reported in fewer than 0.1% of tirzepatide patients, and causation has not been established. Mounjaro slows gastric emptying reversibly in all patients, which is the intended mechanism. True permanent damage is extremely rare and may represent unmasking of pre-existing gastroparesis rather than medication-induced injury.

How common is gastroparesis with Mounjaro? Across clinical trials enrolling more than 5,000 patients, the reported rate of gastroparesis was 0.056%, or roughly 1 in 1,800 patients. Post-market surveillance suggests a rate below 0.01%. For comparison, the background rate of idiopathic gastroparesis in the general population is 0.02% to 0.04% per year.

What are the early warning signs of gastroparesis on Mounjaro? Vomiting undigested food from meals eaten 8 to 12+ hours earlier is the most specific warning sign. Other concerning symptoms include persistent vomiting (more than 3 episodes per day for more than 3 days), inability to keep down liquids, and symptoms that worsen over time rather than improve.

Can you reverse gastroparesis caused by Mounjaro? If gastroparesis is truly caused by Mounjaro (rather than pre-existing), it should reverse within 2 to 3 weeks of stopping the medication as the drug clears from your system. Symptoms that persist beyond 21 days after the last dose suggest a different underlying cause.

Should I avoid Mounjaro if I have a history of GERD or acid reflux? GERD and acid reflux are not contraindications to Mounjaro, but you may experience worsening symptoms during titration due to delayed gastric emptying. Most patients adapt within 4 to 8 weeks. Manage with dietary changes, H2 blockers, or PPIs as needed.

Is gastroparesis more common with Mounjaro than with Ozempic? Published trial data suggests similar rates. Tirzepatide (Mounjaro) has a slightly higher overall GI side effect burden than semaglutide (Ozempic), but the difference in gastroparesis specifically is not statistically significant. Both medications slow gastric emptying through the same GLP-1 receptor mechanism.

What should I do if I start vomiting on Mounjaro? If you vomit once or twice within a few hours of eating, especially after a large or fatty meal, this is common and usually self-limiting. Stay hydrated, eat smaller meals, and monitor. If you vomit more than 3 times in 24 hours or vomit undigested food from many hours prior, contact your provider the same day.

Can Mounjaro cause bowel obstruction? Ileus (intestinal obstruction) has been reported in rare cases (fewer than 20 cases out of millions of patient-years of exposure). The FDA added a warning about ileus to GLP-1 labels in 2023. Symptoms include severe abdominal pain, distension, inability to pass gas or stool, and vomiting. This is a medical emergency.

How long does nausea from Mounjaro last? For most patients, nausea peaks during the first week after starting or escalating doses and improves over 2 to 4 weeks. About 20% to 30% of patients experience nausea during the first month; fewer than 5% have persistent nausea beyond 12 weeks at a stable dose.

Does compounded tirzepatide have the same gastroparesis risk as brand-name Mounjaro? Yes. Both contain tirzepatide and act through the same mechanism. The gastroparesis risk is determined by the active ingredient, not the formulation. Compounded versions may contain additional ingredients like B12, but these do not meaningfully affect gastric motility.

Can I take anti-nausea medication with Mounjaro? Yes. Ondansetron (Zofran), metoclopramide (Reglan), and promethazine (Phenergan) are commonly prescribed for GLP-1-induced nausea. Metoclopramide has the added benefit of promoting gastric emptying, but it carries a risk of movement disorders with long-term use. Discuss options with your provider.

What foods should I avoid on Mounjaro to reduce gastroparesis risk? High-fat foods (fried foods, cream sauces, fatty cuts of meat) slow gastric emptying further and worsen symptoms. Large meals, carbonated beverages, and eating within 3 hours of bedtime also increase symptom risk. Focus on smaller, more frequent meals with lean protein and easily digestible carbohydrates.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Nauck MA et al. Incretin-Based Therapies: Viewpoints on the Way to Consensus. Diabetes Care. 2021.
3. Camilleri M et al. Clinical Guideline: Management of Gastroparesis. American Journal of Gastroenterology. 2018.
4. Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023.
5. Choung RS et al. Risk of Gastroparesis in Subjects With Type 1 and 2 Diabetes in the General Population. Gut. 2012.
6. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying. Clinical Pharmacology & Therapeutics. 2022.
7. FDA Drug Safety Communication. FDA Updates Prescribing Information for GLP-1 Receptor Agonists. September 2023.
8. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
9. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
10. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
11. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
12. Halawi H et al. Gastroparesis: Pathophysiology, Clinical Manifestations, and Treatment. Gastroenterology Clinics of North America. 2020.
13. Bharucha AE et al. Delayed Gastric Emptying Is Associated With Early and Long-term Hyperglycemia in Type 1 Diabetes Mellitus. Gastroenterology. 2015.
14. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Tirzepatide Reports Through Q4 2025. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Zofran is a registered trademark of GlaxoSmithKline. Reglan is a registered trademark of ANI Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.